Funding Round
Nuro Health secures £22M Series A for EEG neurofeedback ADHD therapy platform
TechCrunch Europe4/4/2026·04/04/26🌐 Europe
Summary
London-based Nuro Health raised £22M Series A led by Octopus Ventures, with Northzone and Founders Factory Health. The company's EEG-based neurofeedback platform for pediatric ADHD has completed a 200-child clinical study showing 42% reduction in ADHD symptom scores versus waitlist control. FDA Breakthrough Device designation received.
Why it matters
ADHD affects 9% of children globally and medication is the primary treatment despite significant side effects concerns from parents. A non-drug EEG neurofeedback platform with FDA Breakthrough Device designation has a compelling regulatory and commercial pathway in the US.
#EEG#Mental Health Tech#Wearables#UK
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in